ATA Creativity Global Announces Filing of Annual Report on Form 20-F for the Year Ended December 31, 2024
BEIJING, CN / ACCESS Newswire / April 10, 2025 / ATA Creativity Global ('ACG' or the 'Company', Nasdaq:AACG), an international education services company focused on providing quality learning experiences that cultivate and enhance students' creativity, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission ('SEC'). The annual report can be accessed at the Company's investor relations website at http://ir.atai.net.cn under the section titled 'SEC Filings.'
ACG will provide a hard copy of its annual report for the year ended December 31, 2024, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Company's IR representatives stated below, or at [email protected].
About ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. ATA Creativity Global offers a wide range of education services consisting primarily of portfolio training, research-based learning services, overseas study counselling and other educational services through its training center network. For more information, please visit ACG's website at www.atai.net.cn.
For more information on our company, please contact the following individuals:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus', 'SLP'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O'Connor will host one-on-one meetings with institutional investors on Tuesday, June 17, 2025. For more information about the events or questions about registration, interested parties should reach out to their contacts at Citizens. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
Business Wire
21 minutes ago
- Business Wire
Agentic AI Solutions Can Bypass Legacy Data Challenges, New ISG Study Says
FRANKFURT, Germany--(BUSINESS WIRE)--Agentic AI solutions are being used to address complex enterprise data challenges, with agents being deployed for data monitoring, profiling and enrichment, a new study from global AI-centered technology research and advisory firm Information Services Group (ISG) (Nasdaq: III) says. The new ISG State of the Agentic AI Market report says providers are designing agentic AI solutions that effectively bypass many legacy data challenges. The report findings will be presented at the ISG AI Impact Summit, June 23-24 in Frankfurt. Share The new ISG State of the Agentic AI Market report says 50 percent of organizations engage a service provider to deliver improved data management, but more than half still struggle with legacy data residing in old applications. To accelerate data management adoption and value, providers are designing agentic AI solutions that effectively bypass many legacy data challenges. The report findings will be presented at the ISG AI Impact Summit, June 23–24 at the Westin Grand in Frankfurt. Leaders from Henkel, Mercedes-Benz Tech Innovation, Pfizer, Siemens AG, Merck KGaA, Lufthansa Innovation Hub, FORVIA HELLA, fischer Group and more will join the event to discuss their organization's strategies for fully unlocking AI value. 'Agentic AI is not an IT solution – it's a new way of doing business,' said Olga Kupriyanova, principal consultant, ISG AI and data engineering and co-author of the agentic AI study. 'AI agents interact with data differently than humans. Many leading providers are turning to agentic AI to solve the problems inherited by their enterprise clients by bridging disparate data sources and managed context across domains.' Kupriyanova will present the findings during the ISG Insights session, 'From Hype to Impact: Preparing for the Agentic AI Enterprise,' on the opening day of the ISG AI Impact Summit. The event's opening day will also feature a keynote presentation by Peter Hartmann, head of digital transformation, and Victoria Sibatorkina, global digital transformation manager, on the GenAI journey of multinational chemical and consumer goods company Henkel. Leveraging data for the next phase of AI transformation will be covered in the 'Make an AI Impact: Focus on Your Data' panel discussion, with Daniel Eckelt, head of the FORVIA HELLA digital office, and Alec Sproten, CDAO of fischer Group. In the 'Strategy and Value Realization with AI' panel, Holger Janssen, director of enterprise technology services at FrieslandCampina; Wawi Kantz, director of enterprise AI adoption and enablement at Pfizer, and Pierre Scokaert, IT director, Sonova, will discuss how AI has impacted their operations. Nils Möbus, GenAI product owner at Mercedes-Benz Tech Innovation, will present 'In the Driver's Seat – Best Practices for GenAI Use Case Implementation,' on day two of the event, highlighting use cases for enhancing developer productivity, internal operations and customer experience. Constance Stein, GenAI manager, cosnova GmbH; Connie Hwong, corporate communications GenAI lead at Siemens AG, and Martin Schraub, director and program lead for digital R&D at Merck KGaA, will join the 'Decoding the AI Noise and Uncovering Value' panel to discuss equipping an organization to build and maintain a next-generation, agentic AI-powered data product. In the 'Risk and Reward: AI in Action Today' panel discussion, Christian Hüttermann, lead enterprise architect for Exyte Management GmbH, and Ivan Terekhov, director of research and intelligence for the Lufthansa Innovation Hub, will share a framework for identifying and prioritizing AI use cases with high potential ROI. The afternoon keynote, 'Empowering AI Success: People, Culture and Enterprise Maturity,' will present new research from Dorotea Baljević, principal consultant, ISG EMEA AI lead and co-host of the ISG AI Impact Summit, and Eryn Peters, co-creator of AI Maturity Index. The research explores how regional and cultural differences influence the success of an AI implementation and the true impact of efficiency metrics such as the number of hours saved once an AI system is in place. 'The most successful organizations in our study aren't necessarily saving the most time with AI,' Baljević said. 'The organizations that have aligned their AI implementation approach with their cultural context are achieving sustainable competitive advantage by recognizing that AI adoption is ultimately a human and cultural challenge. In DACH, cultural alignment in AI implementations includes explicit quality assurance frameworks and clearly defined responsibilities.' In the ISG Startup Challenge, entrepreneurs from Focus Tiger, Museful and Scavenger AI GmbH will pitch their business innovations to a panel of judges for an audience vote. IBM, adesso Group, Devoteam, Infosys, Tata Consultancy Services, EY and Accenture are ISG AI Impact Summit event sponsors. CIO Applications, CIO Insights and are media partners. Additional information and registration are available on the event website. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Business Wire
21 minutes ago
- Business Wire
NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the 'Meeting') held on June 11, 2025 and the grant of stock options ('Options') and restricted share units ('RSUs'). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections were as follows: The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, (ii) to approve the Company's amended and restated stock option plan in the form attached as Schedule 'A' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'Stock Option Plan'), and (iii) to approve the Company's amended and restated restricted share unit plan in the form attached as Schedule 'B' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'RSU Plan'). Amendments to the RSU Plan At the Meeting, the Company proposed the adoption of the RSU Plan which was amended to increase the maximum number of common shares of the Company ('Common Shares') issuable thereunder from 3,000,000 Common Shares to 5,000,000 Common Shares. At the Meeting, 99.38% shareholder votes cast were in favour of adopting the RSU Plan. Issuance of Stock Options and Restricted Share Units On June 12, 2025, NeuPath granted an aggregate of 150,000 Options to non-executive directors of the Company at an exercise price of $0.26 per share, with an expiry date of June 12, 2032. The Options are subject to time-based vesting and will fully vest on June 12, 2026. The terms of the Options granted are in accordance with the Stock Option Plan. In addition, on June 12, 2025, the Company granted an aggregate of 60,000 RSUs to the same non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 12, 2026. The terms of the RSUs granted are in accordance with the RSU Plan. About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit
